Cystic Fibrosis Clinical Trial
Official title:
Dissection of Staphylococcus Aureus Infection From Colonization in Cystic Fibrosis Patients, a Non-interventional, Prospective, Longitudinal Multicenter Study.
Staphylococcus aureus is not only one of the first pathogens infecting the airways of cystic
fibrosis (CF) patients, but also a highly prevalent microorganism (>60% of all CF patients;
European and American CF registries; (4,25), which often persists for several years in the
respiratory tract of CF patients.
The purpose of this study is to dissect infection by S. aureus from colonization. Therefore,
the following non-interventional prospective, longitudinal multicenter study will be
conducted to develop the following hypothesis:
CF patients with high bacterial loads are more likely to be infected by S. aureus than
patients with low bacterial loads.
Primary endpoint: bacterial load of sputum cultures
Secondary endpoints:
- nasal carriage
- molecular analysis of S. aureus (Monoclonal/polyclonal)
- serum: S. aureus-specific antibodies, S100A12, IL-8, TNF-alpha
- sputum: S100A12, IL-8, myeloperoxidase
- S. aureus therapy regimens
- lung function tests: FEV1, deltaFVC , deltaMEF25
- BMI development
Inclusion criteria: S. aureus cultures for more than 6 months within the last year, children
(>6 years) and patients, who are able to perform lung function tests Exclusion criteria: P.
aeruginosa and/or B. cepacia cultures from the specimens for more than 6 months within the
last year before recruitment or during the study period In addition to microbiological
investigations and clinical laboratory tests, the actual clinical situation will be
evaluated and reported during the study period. The results of this observational study will
be used to carefully plan a clinical interventional study. Furthermore, with the results it
might be possible to characterize a subpopulation of patients, which is at greater risk for
S. aureus infections.
Protocol synopsis Title: Dissection of Staphylococcus aureus infection from colonization in
cystic fibrosis patients. A non-interventional prospective, 2-year longitudinal multicenter
study
Study objectives: The aim of the study is to dissect S. aureus infection from colonization
of the pathogen in airway secretions of CF patients during a 2 year period by means of a
non-interventional, prospective, longitudinal multicenter study.
The following hypothesis will be developed:
CF patients with high bacterial loads are more likely to be infected by S. aureus than
patients with low bacterial loads.
Definition of infection:
- change in volume, colour or consistency of sputum (exacerbation)
- increased cough
- malaise, fatigue or lethargy
- body temperature more than 38°C
- new or increased hemoptysis
- anorexia or weight loss
- sinus pain or tenderness
- change in sinus discharge
- change in chest sounds
- ten percent decrease in pulmonary function from a previous recorded value (FEV1, MEF25)
- radiographic changes indicative of pulmonary infection
Primary endpoint: bacterial load of sputum cultures [high (>/= 106CFU/ml); low (<106CFU/ml)]
Secondary endpoints are:
- assessment of nasal S. aureus carriage
- serum samples: antibody titres against S. aureus specific antigens; S100A12,
IL-8,TNF-alpha, CRP
- molecular analysis of S. aureus colonization/infection (monoclonal or heteroclonal)
- sputa analysis: activity of S100A12, IL-8 and myeloperoxidase
- antibiotic treatment regimens against S. aureus
- body mass index
- lung function tests: FEV1, deltaFVC, deltaMEF25
Extensive microbiological investigations will be performed when the patients are seen at
their regular visits in the outpatient clinics or if exacerbations occur. During the study
period of 2 years, at least 8 visits to the outpatient clinic should be recorded. The
following clinical parameters will be documented:
- lung function
- body mass index (weight/height)
- antibiotic treatment Diagnosis: CF and positive S. aureus cultures for more than 6
months within the last year Localisation of the study: multicenter study in Germany
Number of centers: Seven centres agreed already to participate in the study. More
centers have been and will be contacted.
Design: non-interventional prospective, longitudinal multicenter study Planned number of
patients/volunteers: 228 Inclusion criteria: positive S. aureus cultures for more than 6
months within the last year; children (>6 years) and patients with CF, who are able to
perform lung function tests Exclusion criteria: Pseudomonas aeruginosa and/or Burkholderia
cepacia colonization or infection for more than 6 months within the last year before
recruitment; patients who have not been colonized with these pathogens before but acquire
them within the study period and are colonized/infected for more than 6 months during the
observation period
;
Observational Model: Case-Only, Time Perspective: Prospective
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT04696198 -
Thoracic Mobility in Cystic Fibrosis Care
|
N/A | |
| Completed |
NCT00803205 -
Study of Ataluren (PTC124™) in Cystic Fibrosis
|
Phase 3 | |
| Terminated |
NCT04921332 -
Bright Light Therapy for Depression Symptoms in Adults With Cystic Fibrosis (CF) and COPD
|
N/A | |
| Completed |
NCT03601637 -
Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del
|
Phase 3 | |
| Terminated |
NCT02769637 -
Effect of Acid Blockade on Microbiota and Inflammation in Cystic Fibrosis (CF)
|
||
| Recruiting |
NCT06030206 -
Lung Transplant READY CF 2: A Multi-site RCT
|
N/A | |
| Recruiting |
NCT06012084 -
The Development and Evaluation of iCF-PWR for Healthy Siblings of Individuals With Cystic Fibrosis
|
N/A | |
| Recruiting |
NCT06032273 -
Lung Transplant READY CF 2: CARING CF Ancillary RCT
|
N/A | |
| Recruiting |
NCT05392855 -
Symptom Based Performance of Airway Clearance After Starting Highly Effective Modulators for Cystic Fibrosis (SPACE-CF)
|
N/A | |
| Recruiting |
NCT06088485 -
The Effect of Bone Mineral Density in Patients With Adult Cystic Fibrosis
|
||
| Recruiting |
NCT04056702 -
Impact of Triple Combination CFTR Therapy on Sinus Disease.
|
||
| Recruiting |
NCT04039087 -
Sildenafil Exercise: Role of PDE5 Inhibition
|
Phase 2/Phase 3 | |
| Completed |
NCT04038710 -
Clinical Outcomes of Triple Combination Therapy in Severe Cystic Fibrosis Disease.
|
||
| Completed |
NCT04058548 -
Clinical Utility of the 1-minute Sit to Stand Test as a Measure of Submaximal Exercise Tolerance in Patients With Cystic Fibrosis During Acute Pulmonary Exacerbation
|
N/A | |
| Completed |
NCT03637504 -
Feasibility of a Mobile Medication Plan Application in CF Patient Care
|
N/A | |
| Recruiting |
NCT03506061 -
Trikafta in Cystic Fibrosis Patients
|
Phase 2 | |
| Completed |
NCT03566550 -
Gut Imaging for Function & Transit in Cystic Fibrosis Study 1
|
||
| Recruiting |
NCT04828382 -
Prospective Study of Pregnancy in Women With Cystic Fibrosis
|
||
| Completed |
NCT04568980 -
Assessment of Contraceptive Safety and Effectiveness in Cystic Fibrosis
|
||
| Recruiting |
NCT04010253 -
Impact of Bronchial Drainage Technique by the Medical Device Simeox® on Respiratory Function and Symptoms in Adult Patients With Cystic Fibrosis
|
N/A |